Soszka T, Olszewski K
Thromb Res. 1986 Jun 15;42(6):835-46. doi: 10.1016/0049-3848(86)90120-9.
Plasminogen activators (PA) and inhibitors of urokinase were determined by a solid phase 125I-fibrin assay in endometrial tissue homogenates from 87 patients. PA was also determined by a histochemical method. Patients were divided according to histopathological diagnosis into three groups; normal, hyperplastic and cancerous. The mean values and S.D. of PA in control endometria, in hyperplastic endometria and in endometrial cancer were 0.68 +/- 0.55 units per mg protein, 1.9 +/- 1.6 units per mg protein and 3.21 +/- 1.03 units per mg protein, respectively. The results of the histochemical assay of PA correlated with the results of 125I-fibrin assay (R = 0.818, p less than or equal to 0.001). The relative PA activity of urokinase-type was the lowest in normal endometrium; it increased in hyperplastic and it was the highest in carcinomatous endometrium. The urokinase inhibitor activity was similar in control and carcinomatous groups; it was slightly but significantly higher in hyperplasia. The results support the contention that PA reflects malignant transformation of endometrial cells. We suggest that determination of PA may facilitate diagnosis and proper treatment of precancerous and cancerous states of endometrium.
采用固相125I - 纤维蛋白分析法测定了87例患者子宫内膜组织匀浆中的纤溶酶原激活剂(PA)和尿激酶抑制剂。PA也采用组织化学方法测定。根据组织病理学诊断将患者分为三组:正常组、增生组和癌组。正常子宫内膜、增生性子宫内膜和子宫内膜癌中PA的平均值及标准差分别为每毫克蛋白0.68±0.55单位、每毫克蛋白1.9±1.6单位和每毫克蛋白3.21±1.03单位。PA的组织化学检测结果与125I - 纤维蛋白检测结果相关(R = 0.818,p≤0.001)。尿激酶型的相对PA活性在正常子宫内膜中最低;在增生性子宫内膜中升高,在癌性子宫内膜中最高。尿激酶抑制剂活性在对照组和癌组中相似;在增生组中略高但有显著差异。这些结果支持了PA反映子宫内膜细胞恶性转化的观点。我们建议,PA的测定可能有助于子宫内膜癌前病变和癌状态的诊断及合理治疗。